Bard Financial Services Inc. Takes $1.35 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)


Share on StockTwits

Bard Financial Services Inc. purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,900 shares of the medical research company’s stock, valued at approximately $1,351,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Norges Bank bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $2,336,640,000. FMR LLC lifted its holdings in Thermo Fisher Scientific by 5.6% in the fourth quarter. FMR LLC now owns 13,022,987 shares of the medical research company’s stock valued at $6,065,847,000 after buying an additional 686,768 shares during the period. BlackRock Inc. lifted its holdings in Thermo Fisher Scientific by 2.2% in the fourth quarter. BlackRock Inc. now owns 29,504,221 shares of the medical research company’s stock valued at $13,742,475,000 after buying an additional 624,512 shares during the period. Bank Julius Baer & Co. Ltd Zurich lifted its holdings in Thermo Fisher Scientific by 473.7% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 641,921 shares of the medical research company’s stock valued at $298,994,000 after buying an additional 530,026 shares during the period. Finally, Veritas Investment Partners UK Ltd. acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $156,804,000. 87.17% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:TMO opened at $466.38 on Thursday. The firm has a 50 day moving average of $456.46 and a 200-day moving average of $470.87. The stock has a market capitalization of $183.66 billion, a PE ratio of 38.23, a PEG ratio of 1.40 and a beta of 0.85. The company has a current ratio of 2.93, a quick ratio of 2.31 and a debt-to-equity ratio of 0.66. Thermo Fisher Scientific Inc. has a 12 month low of $290.52 and a 12 month high of $532.57.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Sunday, January 31st. The medical research company reported $7.09 EPS for the quarter, beating the consensus estimate of $6.56 by $0.53. The company had revenue of $10.55 billion during the quarter, compared to analysts’ expectations of $9.53 billion. Thermo Fisher Scientific had a net margin of 17.12% and a return on equity of 21.35%. The business’s revenue for the quarter was up 54.5% compared to the same quarter last year. During the same period in the previous year, the company earned $3.55 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 19.03 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, April 16th. Investors of record on Tuesday, March 16th will be issued a dividend of $0.26 per share. The ex-dividend date is Monday, March 15th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.22. This represents a $1.04 annualized dividend and a dividend yield of 0.22%. Thermo Fisher Scientific’s payout ratio is 8.42%.

Several equities analysts recently weighed in on TMO shares. Credit Suisse Group increased their price objective on shares of Thermo Fisher Scientific from $556.00 to $580.00 in a report on Tuesday, January 12th. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $535.00 to $575.00 and gave the stock an “overweight” rating in a report on Tuesday, February 2nd. BTIG Research increased their target price on shares of Thermo Fisher Scientific from $540.00 to $590.00 and gave the stock a “buy” rating in a report on Wednesday, February 3rd. UBS Group cut their target price on shares of Thermo Fisher Scientific from $588.00 to $560.00 and set a “buy” rating on the stock in a report on Monday, March 29th. Finally, KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $520.00 target price on the stock in a report on Wednesday, March 24th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $524.45.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Story: How does a reverse stock split work?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.